Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00143
|
|||||
| Drug Name |
Vincristine
|
|||||
| Synonyms |
22-Oxovincaleukoblastine; Indole alkaloid; LCR; Leurocristine; Lilly37231 (1:1 sulfate salt); Liposomal Vincristine; Marqibo; Onco TCS; Oncovin (1:1 sulfate salt); Oncovin (TN); Oncovine; Tecnocris; Tecnocris (TN); VCR; VIN; Vincaleukoblastine, 22-oxo-22-Oxovincaleukoblastine; Vincasar; Vincasar (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Vincristina; Vincristina [DCIT]; Vincristine (INN); Vincristine [INN:BAN]; Vincristinum; Vincristinum [INN-Latin]; Vincrstine; Vincrystine; Vinkristin; Z-D-Val-Lys(Z)-OH
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Acute lymphoblastic leukemia [ICD11: 2B33.0] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C46H56N4O10
|
|||||
| Canonical SMILES |
CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O
|
|||||
| InChI |
InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1
|
|||||
| InChIKey |
OGWKCGZFUXNPDA-XQKSVPLYSA-N
|
|||||
| CAS Number |
CAS 57-22-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 825 | Topological Polar Surface Area | 171 | ||
| Heavy Atom Count | 60 | Rotatable Bond Count | 10 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 12 | |||
| XLogP |
2.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
104029594
, 104310773
, 11431056
, 124892473
, 124892475
, 126687244
, 127301091
, 127301092
, 127301093
, 127301094
, 127301095
, 127301096
, 127301097
, 127301098
, 127301099
, 127301100
, 127301101
, 127301102
, 127301103
, 127301104
, 127301105
, 127301106
, 127301107
, 127301108
, 127301109
, 127301110
, 127301111
, 127301112
, 127301113
, 127301114
, 127301115
, 127301116
, 127301117
, 14717665
, 14889382
, 26757081
, 29224994
, 46507033
, 48424284
, 49854447
, 53788615
, 56312035
, 56314177
, 57323093
, 598397
, 74979043
, 8153716
, 92309095
, 9413
, 96025362
|
|||||
| ChEBI ID |
ChEBI:28445
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP1 | Transporter Info | Multidrug resistance-associated protein 1 | Substrate | [3] | ||
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [4] | ||
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [5] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | P-GP | Transporter Info | Km = 3.7 microM | Spodoptera frugiperda (Sf9) cells-MDR1 | [6] | |
| References | ||||||
| 1 | Vincristine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates. Cancer Chemother Pharmacol. 2006 Dec;58(6):826-34. | |||||
| 3 | Interaction of plant cannabinoids with the multidrug transporter ABCC1 (MRP1). Eur J Pharmacol. 2008 Sep 4;591(1-3):128-31. | |||||
| 4 | Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64. | |||||
| 5 | L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. Toxicol Lett. 2010 Feb 15;192(3):408-18. | |||||
| 6 | Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol. Biochem J. 2007 Jan 15;401(2):597-605. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.